Abstract: A class of pyrimidoheterocyclic compounds, and specifically disclosed is a compound represented by formula (III) or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure provides a dental bleaching guide plate, including a first plate and a second plate, wherein the first plate and the second plate are abutted to form an enclosed deep groove structure, the first plate is provided with a guide hole, a spacing between two opposite side surfaces of the first plate and the second plate is greater than an outer diameter of a neck of a tooth, and there is a gap between the side surfaces of the first plate and the second plate and side surfaces of the tooth. The guide plate can be sleeved onto an exterior of a tooth to inhibit a bleaching agent from coming into contact with other teeth. In addition, a range and an amount of applying a bleaching agent can be accurately controlled, partitioned coloration and bleaching can be implemented, and an administration position can be accurately located.

Abstract: Disclosed are a class of compounds represented by formula (II), and isomers or pharmaceutically acceptable salts thereof.

Abstract: The present invention relates to PDE9 inhibitors, their synthesis, and their use for treatment of benign prostate hyper-plasia, beta thalassemia, and sickle cell disease.

Abstract: A class of pyrimidoheterocyclic compounds, and specifically disclosed is a compound represented by formula (III) or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are a class of compounds having a highly selective inhibition of ROS1, and the use thereof in the preparation of drugs for treating diseases related to abnormal ROS1 kinase expression. Specifically disclosed are compounds represented by formula (IV) and a pharmaceutically acceptable salt thereof.

Abstract: A compound of formula (II), a tautomer thereof or a pharmaceutically acceptable salt thereof, and use thereof in the preparation of medicaments for treating solid tumor-related diseases.

Abstract: Disclosed are a crystal of a carcinogenic fused kinase inhibitor and a preparation method therefor; also disclosed are applications of the crystal in preparing a medicament for treating tumor-related diseases.

Abstract: The present invention relates a process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2 ylmethyl)pyrrolidin-3-yl)-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one, comprising use of the chiral acid (+)-O,O-Dibenzoyl-D-tartaic acid.

Abstract: Disclosed are the solid form, crystalline form, crystal form A of a compound of formula (I), and a preparation method therefor, crystal form B and a preparation method therefor. Also disclosed are use of the solid form, crystalline form, crystal form A, and crystal form B in the preparation of drugs for the treatment of diseases related to FGFR.

Abstract: Provided is a FGFR inhibitor, designating a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. Also provided is the application of a drug for treating solid tumors, such as FGFR related diseases.

Abstract: The present invention discloses a compound of formula (II), a tautomer thereof or a pharmaceutically acceptable salt thereof, and relates to use thereof in preparing a medicament for treating solid tumor-related diseases.

Abstract: The present invention relates to a series of 2,6-dioxaspiro [4,5] decane derivatives and applications thereof in preparation of opiate receptor ? agonist related drugs; and in particular relates to the derivative compounds shown in formula (I), tautomers thereof or pharmaceutically acceptable compositions thereof.

Abstract: A compound of formula (II), a tautomer thereof or a pharmaceutically acceptable salt thereof, and use thereof in the preparation of medicaments for treating solid tumor-related diseases.

Abstract: The present invention relates to a series of 2,6-dioxaspiro [4,5] decane derivatives and applications thereof in preparation of opiate receptor p agonist related drugs; and in particular relates to the derivative compounds shown in formula (I), tautomers thereof or pharmaceutically acceptable compositions thereof.

Abstract: Provided is a FGFR inhibitor, designating a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. Also provided is the application of a drug for treating solid tumors, such as FGFR related diseases.

Abstract: The present invention relates to PDE9 inhibitors, their synthesis, and their use for treatment of benign prostate hyperplasia, beta thalassemia, and sickle cell disease.

Abstract: Disclosed are an antiviral compound and a use thereof in the preparation of a medicament for the treatment of virus infections. Specifically, the present invention relates an imidazole derivative for treating respiratory syncytial virus infection.

Abstract: The present invention relates to novel pyridino[1,2-?]pyrimidone compounds represented by formula (I) or pharmaceutically acceptable salts thereof; and a method of use thereof for treating tumors.

Abstract: Disclosed are an antiviral compound and a use thereof in the preparation of a medicament for the treatment of virus infections. Specifically, the present invention relates an imidazole derivative for treating respiratory syncytial virus infection.